Effects of human immunoglobulin combined with Prednisone in treatment of patients with primary immune thrombocytopenia
Objective:To observe effects of human immunoglobulin combined with Prednisone in treatment of patients with primary immune thrombocytopenia.Methods:A prospective study was conducted on 76 patients with primary immune thrombocytopenia admitted to this hospital from January 2021 to January 2023.According to the random number table method,they were divided into study group and control group,38 cases in each group.The control group was treated with Prednisone acetate tablets,while the study group was treated with human immunoglobulin on the basis of that of the control group.The clinical efficacy,the inflammatory factor[serum C-reactive protein(CRP),serum procalcitonin,white blood cell count(WBC)]levels,and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of the study group was 94.74%,which was significantly higher than 78.95%of the control group,and the difference was statistically significant(P<0.05).After 2 weeks of treatment,the levels of CRP,procalcitonin and WBC in the two groups were lower than those before the treatment,those in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Human immunoglobulin combined with Prednisone in the treatment of the patients with primary immune thrombocytopenia can improve the total effective rate of treatment and reduce the levels of inflammatory factors.Moreover,it is superior to single Prednisone treatment.
Human immunoglobulinPrednisonePrimary immune thrombocytopeniaInflammationAdverse reaction
NETL
NSTL
万方数据
